Analgesics in Switzerland

Analgesics will continue to register a positive performance in current value terms in Switzerland in 2024, driven largely by a notable rise in respiratory illnesses. This resurgence is partly due to reduced immunity as a result of lower viral transmission rates during the COVID-19 pandemic. With the increase in colds and flu, the use of analgesics for symptom relief, such as body aches and fever reduction, is growing.

The Analgesics in Switzerland report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2019-2023, allowing you to identify the sectors driving growth. Forecasts to 2028 illustrate how the market is set to change.

Product coverage: Systemic Analgesics, Topical Analgesics/Anaesthetic.

Data coverage: Market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?

• Get a detailed picture of the Analgesics market;
• Pinpoint growth sectors and identify factors driving change;
• Understand the competitive environment, the market’s major players and leading brands;
• Use five-year forecasts to assess how the market is predicted to develop.